跳到页面内容
pepts.wiki

我们不是医生,此处的内容均不构成医疗建议。请务必先咨询医疗专业人员。 我们为何这样表述

机器翻译,以英文为准。 阅读英文原文

已获许可的药物Stub

PT-141

黑素皮质素受体激动剂(bremelanotide)

一种源自Melanotan II的环肽。作为bremelanotide,它在美国获批用于绝经前女性的性欲低下障碍。

复溶计算器

概览

已获许可的药物

监管机构已在至少一个国家批准其至少一种用途。这并不说明其在许可范围之外的用途。

本页内容尚不完整

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

证据有多强

它攀登到了哪一级

每种药物都要攀登同一架阶梯。大多数化合物从未到达顶端,其所处位置决定了其主张能有多大的依据。

  1. 已获许可的药物: PT-141

    监管机构已审查这些试验,并批准其用于特定用途。

  2. Phase 3

    大型随机试验,通常有数千人,与安慰剂或标准治疗对照。

  3. Phase 2

    中等规模试验,在患有相应疾病的人群中测量剂量与效果的关系。

  4. Phase 1 and early human studies

    首次在人体中进行的研究:安全性以及身体如何处理该物质。

  5. 细胞与动物

    实验室及动物研究。动物实验的结果不等同于人体结果。

114
PubMed 上的论文
84
其中以人为对象的研究
14
随机试验
58
综述

文献数量只说明发表了多少,并不说明结果如何。在 PubMed 上统计的数量: 2026-11-16

处理与复溶

从粉末到测量好的样品

对任何冻干小瓶都是同样的四个步骤。仅指实验室操作,并非用于人体。

  1. 1. 阅读小瓶标签

    标签给出小瓶中肽的质量,单位为毫克。这个数字是所有计算的起点。

  2. 2. 加入稀释剂

    将量好的稀释剂沿玻璃壁缓慢加入。轻轻旋转;摇晃可能损伤肽。

  3. 3. 计算浓度

    浓度等于质量除以体积:10 毫克溶于 2 毫升即为每毫升 5 毫克。

  4. 4. 量取样品

    体积等于所需质量除以浓度。在 U-100 注射器上,1 毫升即 100 单位。

下方的计算器会完成运算并显示计算过程。

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on PT-141 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of PT-141; no amount here is a recommendation.

PT-141: PubMed 上的文献

What PubMed held for PT-141 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

114
papers
84
in humans
16
clinical trials
14
randomized trials
2012: 2 papers122013: 0 papers2014: 2 papers142015: 2 papers2016: 2 papers162017: 5 papers2018: 4 papers182019: 6 papers2020: 7 papers202021: 10 papers2022: 14 papers222023: 8 papers2024: 8 papers242025: 13 papers2026: 12 papers so far26
Papers per year, 2012 to 2026. The most in one year: 14.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. PT-141: a melanocortin agonist for the treatment of sexual dysfunction

    TrialMolinoff PB, Shadiack AM, Earle D, et al. Annals of the New York Academy of Sciences, 2003. PMID 12851303

  2. Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options

    Meta-analysisToledo RG, Winkelman WD, Reyes-Gonzalez D, et al. Journal of minimally invasive gynecology, 2026. PMID 40543759

  3. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women

    Meta-analysisSpielmans GI Journal of sex research, 2021. PMID 33678061

  4. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

    Randomized trialKingsberg SA, Clayton AH, Portman D, et al. Obstetrics and gynecology, 2019. PMID 31599840

  5. Safety Profile of Bremelanotide Across the Clinical Development Program

    Randomized trialClayton AH, Kingsberg SA, Portman D, et al. Journal of women's health (2002), 2022. PMID 35147466

  6. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder

    ReviewMayer D, Lynch SE The Annals of pharmacotherapy, 2020. PMID 31893927

  7. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder

    ReviewCipriani S, Alfaroli C, Maseroli E, et al. Expert opinion on pharmacotherapy, 2023. PMID 36242769

  8. Bremelanotide: First Approval

    ReviewDhillon S, Keam SJ Drugs, 2019. PMID 31429064

Search used: (bremelanotide[tiab] OR "PT-141"[tiab]). Run it on PubMed

研究链接

Also in Hormonal